Rockwell Medical Technologies (RIMT) Triferic Sales Not Material Enough To Even Disclose, Brean Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Rockwell Medical Reports Third Quarter 2015 Results
November 9, 2015 4:01 PM ESTWIXOM, Mich., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the third quarter of 2015.
Q3 2015 Financial Highlights
Sales were $14.4 million, $0.6 million or 4.6% higher than the third quarter of 2014. Gross profit was $2.5 million, a 10.3% increase over Q3 2014. Gross profit margins increased to 17.4% compared to 16.5% in Q3 2014. SG&A expense was $3.8 million, a decrease of... More